A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2002
11/14/2002	WO2002072577A3 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
11/14/2002	WO2002072089A3 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof
11/14/2002	WO2002068417A3 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
11/14/2002	WO2002067764A3 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002062373A3 Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
11/14/2002	WO2002060339A3 Ophthalmic compositions for treating ocular hypertension
11/14/2002	WO2002055014A3 Therapeutic chroman compounds
11/14/2002	WO2002055013A3 Therapeutic chromone compounds
11/14/2002	WO2002055012A3 Therapeutic heterocyclic compounds
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002045688A3 Composition for treatment of inflammatory disorders
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2001097787A3 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
11/14/2002	WO2001073446A8 Alpha 7 nicotinic receptor screening assays
11/14/2002	WO2001035106A3 Methods for identifying and using amyloid-inhibitory compounds
11/14/2002	WO2001024831A9 Polymer stabilized neuropeptides
11/14/2002	US20020169439 Modular infusion device and method
11/14/2002	US20020169336 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
11/14/2002	US20020169322 Use of N-alkylamino-heterocylic compounds for the treatment of migraine
11/14/2002	US20020169317 Oxazinocarbazoles for the treatment of CNS diseases
11/14/2002	US20020169304 Nucleotide sequences coding polypeptide for use in the classification, diagnosis, prevention and treatment of downe's syndrome and alzheimers's diseases
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169208 Oxybutynin analogs; antichloinergic agents; side effect reduction; short half-life; water-soluble metabolites; incontinence; mydriatic and bronchodilator agents; respiratory system disorders; antiperspirants
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169202 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
11/14/2002	US20020169200 Antitumor, antiinflammatory and antiarthritic agents, treating metastasis, restenosis, osteoporosis, inflammation, macular degeneration, and diabetic retinopathy
11/14/2002	US20020169197 Diaryl-enynes
11/14/2002	US20020169186 Tetrahydroquinoline derivatives as glycine antagonists
11/14/2002	US20020169182 Neurotrophin antagonist compositions
11/14/2002	US20020169178 Benzothieno[3,2-c]pyridines as alpha2 antagonists
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169172 Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases
11/14/2002	US20020169170 Arylpiperazines having activity at the serotonin 1A receptor
11/14/2002	US20020169169 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
11/14/2002	US20020169166 Benzimidazoles that are useful in treating sexual dysfunction
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169163 1,2,3,4-tetrahydro-pyrazino(1,2-a)indole derivatives useful in treating obesity, central nerveous system diosrders, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169156 Azacyclooctane and heptane derivatives, their preparation and use in therapy
11/14/2002	US20020169152 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169137 Preventing or inhibiting pathological beta-amyloid plaque formation in conditions such as Alzheimer's disease
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169128 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
11/14/2002	US20020169109 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
11/14/2002	US20020169103 Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
11/14/2002	US20020168763 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
11/14/2002	US20020168754 Nucleotide sequences coding polypeptides for use in the treatment of gastric, testicular, retinal, nervous system and immunological disorders
11/14/2002	US20020168753 In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168710 Anticancer agents; cardiovascular disorders; anticholesterol agents
11/14/2002	US20020168687 Inhibition of tau-tau-association
11/14/2002	US20020168436 Decursinol or derivative thereof as analgesic agent
11/14/2002	US20020168434 Cyclooxygenase inhibitor; anticancer agents, Alzheimer's disease, central nervous system disorders
11/14/2002	US20020168433 Plant extracts; mixture of isoflavones, lignan, saponin, catechin and benzoic acid
11/14/2002	US20020168411 Spill resistant pharmaceutical system
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168344 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
11/14/2002	US20020168338 Compositions and methods for delivery of agents for neuronal regeneration and survival
11/14/2002	DE10123129A1 Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel Deuterated 3-piperidinopropiophenones and pharmaceutical compositions containing them
11/14/2002	DE10122894A1 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
11/14/2002	DE10121982A1 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation
11/14/2002	DE10121638A1 Verfahren zur Herstellung von Imidazopyridinen Process for the preparation of imidazopyridines
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	CA2484596A1 17-methylene-androstan-3alpha-ol analogs as crh inhibitors
11/14/2002	CA2452245A1 Recombinant fusion proteins and the trimers thereof
11/14/2002	CA2446838A1 Novel mutation
11/14/2002	CA2446795A1 Sulfamide, sulfamate, sulfonamide, urea, amide, alpha, alpha-difluoro amide oxalyl diamide, and heterobicycles fkbp-binding ligands
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446666A1 Method for detecting progredient chronic dementia, and associated peptides and detection reagents
11/14/2002	CA2446652A1 Treatment of adhd
11/14/2002	CA2446640A1 .beta.-amyloid peptide-binding proteins and polynucleotides encoding the same
11/14/2002	CA2446480A1 Method of preventing cell death using antibodies to neural thread proteins
11/14/2002	CA2446437A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446380A1 Proteomimetic compounds and methods
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446351A1 Fused heterocyclic compounds
11/14/2002	CA2446120A1 Novel arylheteroalkylamine derivatives
11/14/2002	CA2446051A1 Phthalazine derivatives with angiogenesis inhibiting activity
11/14/2002	CA2445923A1 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	CA2445766A1 Improved process for preparing zolpidem
11/14/2002	CA2445502A1 Method and compositions for treating migraines
11/14/2002	CA2438978A1 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
11/14/2002	CA2435142A1 Kinases and phosphatases
11/14/2002	CA2385809A1 Alkylamide compounds
11/13/2002	EP1256583A1 Pyrimidine-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
11/13/2002	EP1256582A1 1h-imidazopyridine derivatives
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1256345A1 Combination therapy for treatment of psychoses
11/13/2002	EP1256344A1 Remedies for endothelin-induced diseases
11/13/2002	EP1256343A1 Flibanserin for the treatment of extrapyramidal movement disorders
11/13/2002	EP1256340A1 Improved transdermal therapeutic system for the treatment of Parkinson's disease
11/13/2002	EP1256339A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
11/13/2002	EP1256283A2 Phytopharmaceutical food products
11/13/2002	EP1255854A2 Interaction of nmda receptor with protein tyrosine phosphatase
11/13/2002	EP1255844A1 Humanized anti-ccr2 antibodies and methods of use therefor

1 ... 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 ... 1833